Chemoradiotherapy is a treatment that combines chemotherapy with radiation therapy. Also called chemoradiation.
A team of doctors and scientists from the Champalimaud Clinical Centre in Lisbon, Portugal, and the Netherlands Cancer Institute in Amsterdam, has shown that patients with "low" rectal cancer (that is, very close to the anus) who show no sign of their tumors after a course of radio- and chemotherapy can safely choose to postpone invasive and complication-prone surgical procedures.
Lung cancer is the leading cause of cancer death in the United States and approximately 75-80% of all cases are non-small cell lung cancer (NSCLC).
Results from the NRG Oncology phase I clinical trial NRG-GOG 9929 show that utilizing the immunotherapy drug ipilimumab after chemoradiotherapy (CRT) is tolerated in the curative treatment of women with lymph node-positive cervical cancer.
The UK is all set to launch its run into the future as the undisputed leader in the field of personalized and effective radiation therapy. The proposal is undergirded by a whopping £56 million, which will be used to set up and fund advanced radiation therapy research by a new collaborative setup, Cancer Research UK RadNet, over five years. This is the largest sum ever invested by this organization into radiotherapy research.
Researchers from Charité - Universitätsmedizin Berlin and the German Cancer Consortium have successfully solved a longstanding problem in the diagnosis of head and neck cancers.
Researchers at Trinity College Dublin have identified, for the first time in esophageal cancer, the cancer killing capability of a lesser-known type of immune cell, presenting a new potential therapeutic target.
A new special edition of the International Journal of Radiation Oncology* Biology* Physics focuses on the roles of imaging in radiation oncology. The collection explores topics such as improving accuracy with patient positioning, defining radiation therapy volumes using imaging, imaging of functional biomarkers, the role of imaging in post-treatment care, machine learning and artificial intelligence.
The European Society of Coloproctology has undertaken a major international audit of colorectal operations to understand which are most widely used techniques across the world, which appear to be associated with the best outcomes and where further research needs to be undertaken.
Non-small cell lung cancer patients survive longer when their treatment includes durvalumab following platinum-based chemoradiotherapy, according to research led by Moffitt Cancer Center.
About 50,000 people in the U.S. are diagnosed annually with head, neck, nasal and oral cancers. Most are treated with radiation, and of those, 70-80 percent develop a painful and debilitating side effect called severe oral mucositis.
Atlantic Health System is now enrolling patients in four pancreatic cancer clinical trials. Angela Alistar, MD, a nationally known expert on pancreatic cancer, is serving as national Principal Investigator on the first trial and as local PI on three other trials.
A coveted British Medical Journal award was recently bestowed on the Papillon Contact X-ray Brachytherapy team at the Clatterbridge Cancer Centre. The Cancer Care Team of the year category was won by the entry—Papillon for Rectal Cancer.
It’s unclear whether all patients with advanced rectal cancer need chemoradiotherapy, or whether some can forego the treatment and therefore be spared its side effects.
Analysis of a clinical trial, RTOG Foundation 3504, finds that nivolumab immunotherapy can be administered safely in conjunction with radiation therapy and chemotherapy for patients with newly diagnosed local-regionally advanced head and neck cancers.
A new study has identified a way to turn a humble cocktail of bacteria and vegetables into a targeted system that finds and kills colorectal cancer cells.
A blood test for the human papillomavirus, or HPV, may help researchers forecast whether patients with throat cancer linked to the sexually transmitted virus will respond to treatment, according to preliminary findings from the University of North Carolina Lineberger Comprehensive Cancer Center.
Female patients with locally advanced esophageal cancer that is treated with chemotherapy and radiation therapy before surgery are more likely to have a favorable response to the treatment than male patients are, and women are less likely to experience cancer recurrence, according to a study published online today in The Annals of Thoracic Surgery.
A late breaking subanalysis of the phase III CONVERT trial presented at the European Lung Cancer Conference shows that white blood cell boosting drugs are safe during concurrent chemo-radiotherapy of small cell lung cancer (SCLC).
Elderly patients with early-stage esophageal cancer that received treatment had an increased 5-year overall survival when compared to patients who received observation with no treatment.
The American Society for Radiation Oncology today issued a new clinical guideline for the management of oropharyngeal cancer.